Please wait

Total Return Securities Fund
 
Schedule of Investments
 
March 31, 2025 (Unaudited)
 
   
COMMON STOCKS - 22.0%
 
Shares
   
Value
 
Food - 15.0%
       
Aryzta AG (a)
   
1,189,000
   
$
2,635,354
 
Nestle SA
   
163,900
     
16,550,241
 
             
19,185,595
 
                 
Healthcare- Products - 1.2%
         
Spineart SA (a)(b)
   
221,085
     
1,511,799
 
                 
Retail - 5.8%
         
Cie Financiere Richemont SA
   
43,400
     
7,502,718
 
TOTAL COMMON STOCKS (Cost $15,522,711)
     
28,200,112
 
                 
MASTER LIMITED PARTNERSHIPS - 0.3%
 
Units
   
Value
 
Biotechnology - 0.3%
         
Aravis Biotech II, Limited Partnership (a)(b)(c)
   
3,294,705
     
440,833
 
TOTAL MASTER LIMITED PARTNERSHIPS (Cost $213,885)
     
440,833
 
                 
CLOSED-END FUNDS - 0.0%(d)
 
Shares
   
Value
 
Central Securities Corp.
   
200
     
8,992
 
TOTAL CLOSED-END FUNDS (Cost $8,974)
     
8,992
 
                 
TOTAL INVESTMENTS - 22.3% (Cost $15,745,570)
     
28,649,937
 
Money Market Deposit Account - 76.3% (e)
     
97,601,401
 
Other Assets in Excess of Liabilities - 1.4%
     
1,749,218
 
TOTAL NET ASSETS - 100.0%
         
$
128,000,556
 

     

Percentages are stated as a percent of net assets.
     


THE SWISS HELVETIA FUND, INC.
 
 
                                     
March 31, 2025
 
(continued)
                                               
(a) Non-income producing security.
 
(b) Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation Designee. These securities represented $1,952,632 or 1.5% of net assets as of March 31, 2025.
 
(c) Affiliated security as defined by the Investment Company Act of 1940.
                               
                                                 
   
Value
   
Gross
   
Gross
   
Corporate
   
Realized
   
Unrealized
   
Interest
   
Value
 
Name of Issuer
 
as of 12/31/24
   
Additions
   
Reductions
   
Actions
   
Gain/(Loss)
   
Gain/(Loss)
   
Income
   
as of 3/31/25
 
Aravis Biotech II, Limited Partnership
 
$
427,248
   
$
-
   
$
-
   
$
-
   
$
-
   
$
13,585
   
$
-
   
$
440,833
 
   
$
427,248
   
$
-
   
$
-
   
$
-
   
$
-
   
$
13,585
   
$
-
   
$
440,833
 
                                                                 
(d) Represents less than 0.05% of net assets.
 
(e)The U.S. Bank Money Market Deposit Account (the “MMDA”) is a short-term vehicle in which the Fund holds cash balances. The MMDA will bear interest at a variable rate that is determined based on market conditions and is subject to change daily. The rate as of March 31, 2025 was 3.31%.
 
                                                                 
See Notes to Schedule of Investments
 

PORTFOLIO HOLDINGS
     
% of Net Assets as of March 31, 2025
     
Food
   
15.0
%
Healthcare-Products
   
1.2
%
Retail
   
5.8
%
Biotechnology
   
0.3
%
Closed-End Funds
   
0.0
%
Money Market Deposit Account
   
76.3
%
Other Assets Less Liabilities
   
1.4
%
     
100
%

TOP 10 PORTFOLIO HOLDINGS
     
% of Net Assets as of March 31, 2025
     
Nestle SA
   
12.93
%
Cie Financiere Richemont SA
   
5.86
%
Aryzta AG
   
2.06
%
SPINEART SA
   
1.18
%
ARAVIS BIOTECH II LP
   
0.34
%
Central Securities Corp
   
0.01
%

TOTAL RETURN SECURITIES FUND

 
Notes to Schedule of Investments (Unaudited)

Total Return Securities Fund has adopted authoritative fair value accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.

Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include  quoted  prices for the  identical  instrument on  an  inactive  market,  prices for  similar instruments,  interest  rates,  prepayment  speeds,  credit risk, yield  curves, default rates and similar data.

Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The following is a summary of the fair valuation hierarchy of the Fund’s securities as of March 31, 2025:

TOPIC 820 TABLE
 
                               
Investments in Securities*
 
Level 1
Quoted Prices
   
Level 2
Other Significant
Observable Inputs
   
Level 3
Significant
Unobservable Inputs
   
Investments Valued
at NAV**
   
Total
 
Common Stock
 
$
26,688,313
   
$
-
   
$
1,511,799
   
$
-
   
$
28,200,112
 
Master Limited Partnerships
   
-
     
-
     
-
     
440,833
     
440,833
 
Closed-End Funds
   
8,992
     
-
     
-
     
-
     
8,992
 
Total Investments in Securities
 
$
26,697,305
   
$
-
   
$
1,511,799
   
$
440,833
   
$
28,649,937
 
 
* Please see the Schedule of Investments for industry classifications.
**   As of March 31, 2025, certain of the Fund’s investments were valued using net asset value (“NAV”) per share (or its equivalent) as a practical expedient for fair value and have been excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented in the schedule of investments.
 
The Fund values its investment in a private equity limited partnership in accordance with Accounting Standards Codification 820-10-35, “Investments in Certain Entities that Calculate Net Asset Value Per Share (Or its Equivalent)” (“ASC 820-10-35”). ASC 820-10-35 permits a reporting entity to measure the fair value of an investment that does not have a readily determinable fair value, based on the NAV of the investment as a practical expedient, without further adjustment, unless it is probable that the investment will be sold at a value significantly different than the NAV. If the NAV of the investment is not as of the Fund’s measurement date, then the NAV should be adjusted to reflect any significant events that may change the valuation. Inputs and valuation techniques for these adjustments may include fair valuations of the partnership and its portfolio holdings provided by the partnership’s general partner or manager, other available information about the partnership’s portfolio holdings, values obtained on redemption from other limited partners, discussions with the partnership’s general partner or manager and/or other limited partners and comparisons of previously-obtained estimates to the partnership’s audited financial statements. In using the unadjusted NAV as a practical expedient, certain attributes of the investment that may impact its fair value are not considered. Attributes of those investments include the investment strategies of the privately held companies and may also include, but are not limited to, restrictions on the investor’s ability to redeem its investments at the measurement date and any unfunded commitments.

Level 3 securities, which are listed in Note 3 to the Schedule of Investments, consist of the Fund’s investments in privately-held companies.

Inputs and valuation techniques used by the Fund to value its Level 3 investments in privately-held companies may include the following: acquisition cost; fundamental analytical data; discounted cash flow analysis; nature and duration of restrictions on disposition of the investment; public trading of similar securities of similar issuers; economic outlook and condition of the industry in which the issuer participates; financial condition of the issuer; and the issuer’s prospects, including any recent or potential management or capital structure changes. Although these valuation inputs may be observable in the marketplace as is characteristic of Level 2 investments, the privately-held companies, categorized as Level 3 investments, generally are highly illiquid in terms of resale.
 
When valuing Level 3 investments, management also may consider potential events that could have a material impact on the operations of a privately held company. Not all of these factors may be considered or available, and other relevant factors may be considered on an investment-by-investment basis.

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.
 
LEVEL 3 ROLLFORWARD TABLE
 
             
   
Common Stock
   
Total
 
Balance as of December 31, 2024
 
$
1,400,307
   
$
1,400,307
 
Change in Unrealized Appreciation/Depreciation
   
111,492
     
111,492
 
Net Realized Gain (Loss)
   
-
     
-
 
Gross Purchases
   
-
     
-
 
Gross Sales
   
-
     
-
 
Transfer out of Level 3
   
-
     
-
 
Balance as of March 31, 2025
 
$
1,511,799
   
$
1,511,799
 
Change in unrealized appreciation (depreciation) during the period for Level 3 investments held at March 31, 2025
   
111,492
     
111,492
 
(a)
The noted amounts of change in unrealized appreciation/depreciation relate to the fair value of Level 3 assets held on March 31, 2025.